دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Pulmonary hypertension, sarcoidosis, and inflammatory and dilated cardiomyopathy: new light shed on prevalence, mechanisms, and treatment
Filippo Crea
doi : 10.1093/eurheartj/ehac497
European Heart Journal, Volume 43, Issue 36, 21 September 2022, Pages 3371–3375
Atrial fibrillation and heart failure: novel insights into the chicken and egg dilemmaÂ
Steffen Pabel, Samuel Sossalla
doi : 10.1093/eurheartj/ehac257
European Heart Journal, Volume 43, Issue 36, 21 September 2022, Pages 3376–3378
Global impact of deep vein thrombosis awareness month: challenges and future recommendationsÂ
Kashish Malhotra, Ashvind Bawa, Kashish Goyal, Gurpreet Singh Wander
doi : 10.1093/eurheartj/ehac252
European Heart Journal, Volume 43, Issue 36, 21 September 2022, Pages 3379–3381
Supporting cardiovascular researchers takes a village but it starts with usÂ
Francine Z Marques, Emma Thomas, Niamh Chapman
doi : 10.1093/eurheartj/ehac366
European Heart Journal, Volume 43, Issue 36, 21 September 2022, Pages 3382–3384
Less weight, less cancer? The potential positive effects of bariatric surgery beyond cardiovascular risk reductionÂ
Rocco Vergallo, Giovanna Liuzzo
doi : 10.1093/eurheartj/ehac388
European Heart Journal, Volume 43, Issue 36, 21 September 2022, Pages 3385–3386
Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS studyÂ
Luca Valerio, Anna C Mavromanoli, Stefano Barco, Christina Abele, Dorothea Becker, Leonhard Bruch, Ralf Ewert, Martin Faehling, David Fistera, Felix Gerhardt, Hossein Ardeschir Ghofrani, Aleksandar Grgic, Ekkehard Grünig, Michael Halank, Matthias Held, Lukas Hobohm, Marius M Hoeper, Frederikus A Klok, Mareike Lankeit, Hanno H Leuchte, Nadine Martin, Eckhard Mayer, F Joachim Meyer, Claus Neurohr, Christian Opitz, Kai Helge Schmidt, Hans Jürgen Seyfarth, Rolf Wachter, Heinrike Wilkens, Philipp S Wild, Stavros V Konstantinides, Stephan Rosenkranz, FOCUS Investigators
doi : 10.1093/eurheartj/ehac206
European Heart Journal, Volume 43, Issue 36, 21 September 2022, Pages 3387–3398
To systematically assess late outcomes of acute pulmonary embolism (PE) and to investigate the clinical implications of post-PE impairment (PPEI) fulfilling prospectively defined criteria.
FOCUS on sequelae of acute pulmonary embolism: does it pay off?Â
Irene M Lang, Tyler Artner
doi : 10.1093/eurheartj/ehac170
European Heart Journal, Volume 43, Issue 36, 21 September 2022, Pages 3399–3401
Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trialÂ
Theresa Marie Dachs, Franz Duca, René Rettl, Christina Binder-Rodriguez, Daniel Dalos, Luciana Camuz Ligios, Andreas Kammerlander, Ekkehard Grünig, Ingrid Pretsch, Regina Steringer-Mascherbauer, Klemens Ablasser, Manfred Wargenau, Julia Mascherbauer, Irene M Lang, Christian Hengstenberg, Roza Badr-Eslam, Johannes Kastner, Diana Bonderman
doi : 10.1093/eurheartj/ehac389
European Heart Journal, Volume 43, Issue 36, 21 September 2022, Pages 3402–3413
The presence of pulmonary hypertension (PH) severely aggravates the clinical course of heart failure with preserved ejection fraction (HFpEF).
Targeting pulmonary hypertension in patients with heart failure and preserved ejection fraction: rather static than DYNAMIC development?Â
Johann Bauersachs, Karen M Olsson
doi : 10.1093/eurheartj/ehac387
European Heart Journal, Volume 43, Issue 36, 21 September 2022, Pages 3414–3416
Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implicationsÂ
Kazunori Omote, Hidemi Sorimachi, Masaru Obokata, Yogesh N V Reddy, Frederik H Verbrugge, Massar Omar, Hilary M DuBrock, Margaret M Redfield, Barry A Borlaug
doi : 10.1093/eurheartj/ehac184
European Heart Journal, Volume 43, Issue 36, 21 September 2022, Pages 3417–3431
Pulmonary hypertension (PH) and pulmonary vascular disease (PVD) are common and associated with adverse outcomes in left heart disease (LHD). This study sought to characterize the pathophysiology of PVD across the spectrum of PH in LHD.
Was Paul Wood wrong about pre-capillary pulmonary hypertension protecting against pulmonary congestion in left heart disease?Â
Marius M Hoeper, Stephan Rosenkranz
doi : 10.1093/eurheartj/ehac176
European Heart Journal, Volume 43, Issue 36, 21 September 2022, Pages 3432–3434
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trialÂ
Wolfram Doehner, Stefan D Anker, Javed Butler, Faiez Zannad, Gerasimos Filippatos, João Pedro Ferreira, Afshin Salsali, Carolyn Kaempfer, Martina Brueckmann, Stuart J Pocock, James L Januzzi, Milton Packer
doi : 10.1093/eurheartj/ehac320
European Heart Journal, Volume 43, Issue 36, 21 September 2022, Pages 3435–3446
The sodium-glucose cotransporter-2 inhibitor empagliflozin decreases the risk of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with reduced ejection fraction.
Serum uric acid lowering with empagliflozin in heart failure with reduced ejection fraction: a sweet added benefit?Â
Isla S Mackenzie, Thomas M MacDonald
doi : 10.1093/eurheartj/ehac415
European Heart Journal, Volume 43, Issue 36, 21 September 2022, Pages 3447–3449
Risk stratification of patients with cardiac sarcoidosis: the ILLUMINATE-CS registryÂ
Takeru Nabeta, Takeshi Kitai, Yoshihisa Naruse, Tatsunori Taniguchi, Kenji Yoshioka, Hidekazu Tanaka, Takahiro Okumura, Shuntaro Sato, Yuichi Baba, Keisuke Kida, Yodo Tamaki, Shingo Matsumoto, Yuya Matsue
doi : 10.1093/eurheartj/ehac323
European Heart Journal, Volume 43, Issue 36, 21 September 2022, Pages 3450–3459
This study evaluated the prognosis and prognostic factors of patients with cardiac sarcoidosis (CS), an underdiagnosed disease.
Cardiac sarcoidosis: growing evidence in risk stratificationÂ
Benjamin Meder, Jan Koelemen
doi : 10.1093/eurheartj/ehac411
European Heart Journal, Volume 43, Issue 36, 21 September 2022, Pages 3460–3462,
Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy: 20-year follow-up of the TIMIC trialÂ
Cristina Chimenti, Matteo Antonio Russo, Andrea Frustaci
doi : 10.1093/eurheartj/ehac348
European Heart Journal, Volume 43, Issue 36, 21 September 2022, Pages 3463–3473,
Long-term results of the Tailored IMmunosuppression in virus-negative Inflammatory Cardiomyopathy (TIMIC) trial protocol have been evaluated.
Advanced diagnostics in inflammatory cardiomyopathy for personalized therapeutic decision-makingÂ
Heinz Peter Schultheiss, Felicitas Escher
doi : 10.1093/eurheartj/ehac412
European Heart Journal, Volume 43, Issue 36, 21 September 2022, Pages 3474–3476
Serine biosynthesis as a novel therapeutic target for dilated cardiomyopathyÂ
Isaac Perea-Gil, Timon Seeger, Arne A N Bruyneel, Vittavat Termglinchan, Emma Monte, Esther W Lim, Nirmal Vadgama, Takaaki Furihata, Alexandra A Gavidia, Jennifer Arthur Ataam, Nike Bharucha, Noel Martinez-Amador, Mohamed Ameen, Pooja Nair, Ricardo Serrano, Balpreet Kaur, Dries A M Feyen, Sebastian Diecke, Michael P Snyder, Christian M Metallo, Mark Mercola, Ioannis Karakikes
doi : 10.1093/eurheartj/ehac305
European Heart Journal, Volume 43, Issue 36, 21 September 2022, Pages 3477–3489
Genetic dilated cardiomyopathy (DCM) is a leading cause of heart failure. Despite significant progress in understanding the genetic aetiologies of DCM, the molecular mechanisms underlying the pathogenesis of familial DCM remain unknown, translating to a lack of disease-specific therapies.
Activation of an accessory pathway of glucose metabolism to treat dilated cardiomyopathyÂ
Thomas Eschenhagen
doi : 10.1093/eurheartj/ehac397
European Heart Journal, Volume 43, Issue 36, 21 September 2022, Pages 3490–3492
Atrial functional assessment at rest and during exercise stress in left ventricular diastolic dysfunctionÂ
Sören J Backhaus, Andreas Schuster
doi : 10.1093/eurheartj/ehac418
European Heart Journal, Volume 43, Issue 36, 21 September 2022, Pages 3493–3494
Importance of cardiac magnetic resonance imaging assessment of left ventricular filling pressure at resting stateÂ
Pankaj Garg, Andrew J Swift
doi : 10.1093/eurheartj/ehac420
European Heart Journal, Volume 43, Issue 36, 21 September 2022, Page 3495
Starr–Edwards tricuspid valve in a patient with Ebstein anomaly: older than half of the century and still functioning well
Michal Orczykowski, Ilona Michalowska, Ewa Kowalik, Piotr Hoffman, �ukasz Szumowski
doi : 10.1093/eurheartj/ehac331
European Heart Journal, Volume 43, Issue 36, 21 September 2022, Page 3496
A case of hypoplastic posterior mitral leaflet–related severe mitral regurgitation associated with ostium secundum atrial septal defect
Akinchan Bhardwaj, Ajith Ananthakrishna Pillai, Sridhar Balaguru
doi : 10.1093/eurheartj/ehac371
European Heart Journal, Volume 43, Issue 36, 21 September 2022, Page 3497
